Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor 2, has demonstrated encouraging anti-cancer activity in gastric cancer within both in vitro and in vivo models. Its therapeutic efficacy, tolerability and safety have been evaluated in one Phase II and one Phase III study in metastatic/advanced gastric cancer. In this review, we focus on the mechanism of action of apatinib, its pharmacokinetic profile and its clinical activity in the treatment of advanced/metastatic gastric cancer.
Introduction
Gastric cancer (GC) is the fifth most common cancer worldwide and, despite improvements in the treatment of this disease, GC is the third most common cancer-related cause of death in the world Unfortunately, after failure of second-line treatment, the results of further lines of chemotherapy are disappointing (based on results in human epidermal receptor 2 (HER-2) positive GC), and no chemotherapeutic agents showed a clear benefit in prolonging survival [6] . Therefore, the discovery of novel, effective and safe treatment options is an unmet clinical need for metastatic GC.
Apatinib, also known as YN968D1, is a novel receptor tyrosine kinase inhibitor selectively targeting the intracellular ATP-binding site of vascular endothelial growth factor receptor 2 (VEGFR2) [7, 8] . Evidence that apatinib treatment provides a clinical benefit in patients with metastatic GC is now available. This review will examine the role of apatinib in GC, with references to its proposed mechanism of action, as well as its efficacy, safety, and tolerability in clinical trials. Unfortunately, very few data are available on the use of chemotherapy in the third-line setting: only taxane or irinotecan-based regimens have shown modest effects on survival with a very low rate of response [15] [16] . Recent reports suggest that regorafenib, a pan-receptor tyrosine kinase inhibitor, may have some activity in GC [17] . The INTEGRATE study showed a progression free survival advantage for regorafenib compared to placebo in refractory advanced GC patients who had already progressed after first and second line therapy [17] . Due to these newly available treatment options, the number of patients with metastatic GC who have been treated with several lines of therapy will increase. Amongst the newly available biological therapies available for the treatment of GC, apatinib has shown promising activity [18] and will be the subject of this review.
Introduction to the drug

Chemistry
Apatinib is an orally bioavailable small-molecule anti-angiogenic agent, with a molecular weight of 493.58 Da, that potently inhibits VEGFR2, whilst also have some activity for inhibition of the platelet-derived growth factor receptor-β (PDGFR-β), c-kit, and c-src 
Pharmacokinetics and metabolism
The pharmacokinetics and metabolism of apatinib have been studied. After administration of apatinib to human subjects, the time to maximum plasma concentration level was ~4 hours after dosing and the mean half-life was 9 hours [23]. In three different dosing regimens (500, 750 and 800), a dose-dependent C max and AUC 24 were observed with C max of 1,521, 2,379, and 2,833 ng/mL and AUC 24 
Clinical efficacy
Phase I study
The clinical development of apatinib has been carried out mostly in China. In 2010, a phase I study was performed to determine the pharmacological activity and the maximum tolerated dose (MTD) of apatinib for patients with advanced solid tumors [23]. Thirty-four patients enrolled in the study had gastrointestinal tract-related tumors. The study established that the MTD for apatinib was 850 mg once daily. Moreover, a significant antitumor activity was also observed in patients with measurable lesions; the 7 patients achieving partial response were mainly those with GC tumors.
The most frequently observed drug-related adverse events were hypertension, proteinuria, and hand-foot syndrome (which are all common drug class effects of oral VEGFR2 tyrosine kinase inhibitors) and they were clinically manageable. 
Safety and tolerability
In the phase I trial [23], the most frequently observed drug-related adverse events with apatinib were hypertension (69.5%, 29 grade 1-2 and three grade 3-4), proteinuria (47.8%, 16 grade 1-2 and six grade 3-4), and hand-foot syndrome (45.6%, 15 grade 1-2 and six grade 3-4). Eighteen patients had a dose reduction due to different toxicities. In the phase II trial, grade 3-4 adverse events occurred in more than 5% of patients [26] and the most frequent were: hand-foot syndrome, hypertension, thrombocytopenia, anemia, diarrhea, and liver toxicity (mainly, elevation of aminotransferase and bilirubin levels). The most frequently observed grade 3-4 adverse events were hand-foot syndrome and hypertension detected in the 10% of the patients. Fatigue was a common adverse event, affecting a total of 10.4%, 17.0%, and 15.2% of patients receiving placebo, apatinib 850 mg once daily, or apatinib 425 mg twice daily, respectively.
In the phase III trial [27], dose modifications resulting from toxicity were more common in the apatinib arm compared to the placebo arm (21.0% versus 3.3%, respectively). The main reasons for dose reduction were hand-foot syndrome, proteinuria, and hypertension. A grade 3-4 hand-foot syndrome occurred in 8.5% and 0% of patients in the apatinib and placebo group, respectively (P=0.0032). Grade 3-4 hypertension and proteinuria occurred in 4.5% and 2.3% of patients in the apatinib group, but was 0% in the placebo group. Grade 3-4 neutropenia, transaminase elevation and hypophosphatemia were also increased in the apatinib arm. Details of adverse events from these studies are provided in Table 1 .
Regulatory affairs
Based on the data from the phase III study, apatinib was approved in October 2014 by the China Food and Drug Administration (CFDA) for patients with metastatic gastric or gastroesophageal junction adenocarcinoma after the second-line of chemotherapy [28].
Conclusion
Apatinib is a novel, orally bioavailable small-molecule tyrosine kinase inhibitor of VEGFR2 that appears to be a promising agent in the treatment of a variety of tumor types including metastatic GC. However, although the initial clinical results are promising, it should be stated that the small number of patients recruited in these clinical trials does preclude definitive conclusions at the current time. Nonetheless, apatinib compared to placebo has been shown to improve overall survival, progression free survival and response rate in heavily pre-treated patients (i.e. those Approval was based on gains in overall survival when the drug was administered either alone or in combination with paclitaxel in phase III studies [11] . Of note, although ramucirumab and apatinib target the same signalling pathway, they have different mechanisms of action. However, their efficacy in GC suggests an important role for VEGF receptor signalling in GC. Nonetheless the clinical advantage seems modest (around two months gain in both progression free survival and overall survival). Since apatinib is the first tyrosine-kinase inhibitor shown to be effective in metastatic GC, the continued clinical exploitation of this drug for metastatic GC is warranted.
Expert commentary
It should be noted that although the clinical studies performed so far support the use of apatinib in GC, this may be mainly due to the real absence of an efficacious treatment as a comparator.
Therefore, the real clinical efficacy of apatinib is still to be weighed in larger trials.
It is also important to consider whether a subset of GC patients can be selected which optimally respond to apatinib. The Cancer Genome Atlas Research Network (TCGA) has demonstrated a subset of GC with a recurrent amplification of the VEGF-A gene and with an elevated expression of angiogenesis-related pathways [31-34]. In addition, several trials showed that the expression of VEGFR2 is related to a poor prognosis in patients with metastatic GC [35] . Given the molecular evidence that the VEGF pathway is upregulated in only a subset of GC cancers, it may be beneficial to pursue predictive biomarkers for anti-VEGF pathway therapies in this cancer. This would help in selecting the right patients to treat with apatinib. One potential candidate for such a biomarker is the expression level or activation status of VEGFR2 in GC. In this context, a study of apatinib in patients with breast cancer showed that both hypertension and high expression of phosphorylated VEGFR2 could serve as potential biomarkers for treatment efficacy [36] . Unfortunately, as yet, there is no definitive biomarker data for apatinib in GC.
Five-year view
The efficacy and safety of apatinib in metastatic GC will be evaluated in an on-going phase IV study (NCT02426034) already started in April 2015. A total of 2000 patients are planned to be enrolled. Undoubtedly, this large study will provide important information as to the clinical role of apatinib in the second line treatment of GC. Additional studies will investigate the role of apatinib as a maintenance therapy after the first line of treatment in GC. Apatinib will be also investigated in combination with chemotherapeutic agents such as S-1 in the first-line of treatment or S- 1/paclitaxel based chemotherapy in the conversion therapy of metastatic GC [37] . Details of these trials are provided in Table 2 .
Key issues
• Apatinib is a novel receptor tyrosine kinase inhibitor selectively targeting the intracellular ATP-binding site of the vascular endothelial growth factor receptor 2 (VEGFR2)
• Apatinib compared to placebo has been shown to improve survival, progression free survival and response rate in heavily pre-treated GC patients.
• The toxicities of apatinib were tolerable or clinically manageable. Hypertension, hand-andfoot syndrome, proteinuria, fatigue, anorexia, and elevated aminotransferase were the most commonly observed adverse events.
Information resources
Basic information on the chemistry and properties of apatinib can be obtained from the online Salix Pharmaceuticals drug information or from the PubChem website. For an overview of the diagnosis and management of GC, please see the American College of Gastroenterology. For references directly pertaining to the action or use of apatinib please see the recommended references below. 
